Fabrication of Poly(<svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.2552099pt" id="M1" height="8.2614pt" version="1.1" viewBox="-0.0657574 -8.00619 7.95135 8.2614" width="7.95135pt"><g transform="matrix(.017,0,0,-0.017,0,0)"><path id="g5-247" d="M433 380C433 415 386 454 286 454C188 454 82 415 82 325C82 279 111 250 171 239V237C84 220 21 182 21 110C21 37 87 -12 195 -12C299 -12 378 37 427 100L406 130C362 88 306 64 254 64C210 64 171 94 171 140C171 184 207 216 267 216C288 216 311 215 326 214L364 268L358 275C338 273 315 272 295 272C245 272 212 298 212 337C212 374 239 415 287 415C330 415 351 377 361 347C365 334 369 330 374 330C396 330 433 355 433 380Z"/></g></svg>-caprolactone) Scaffolds Reinforced with Cellulose Nanofibers, with and without the Addition of Hydroxyapatite Nanoparticles

<div>Cytotoxicity assessment: extract results.</div>

BioMed Research International

fig8

Figure 8

Figure 8: Fabrication of Poly(<svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.2552099pt" id="M1" height="8.2614pt" version="1.1" viewBox="-0.0657574 -8.00619 7.95135 8.2614" width="7.95135pt"><g transform="matrix(.017,0,0,-0.017,0,0)"><path id="g5-247" d="M433 380C433 415 386 454 286 454C188 454 82 415 82 325C82 279 111 250 171 239V237C84 220 21 182 21 110C21 37 87 -12 195 -12C299 -12 378 37 427 100L406 130C362 88 306 64 254 64C210 64 171 94 171 140C171 184 207 216 267 216C288 216 311 215 326 214L364 268L358 275C338 273 315 272 295 272C245 272 212 298 212 337C212 374 239 415 287 415C330 415 351 377 361 347C365 334 369 330 374 330C396 330 433 355 433 380Z"/></g></svg>-caprolactone) Scaffolds Reinforced with Cellulose Nanofibers, with and without the Addition of Hydroxyapatite Nanoparticles 

Figure 8 | Fabrication of Poly(-caprolactone) Scaffolds Reinforced with Cellulose Nanofibers, with and without the Addition of Hydroxyapatite Nanoparticles 